Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Odronextamab in Treatment Naïve Low Tumor Volume Advanced Stage Follicular Lymphoma
NCT07128641Phase 2Recruiting
- Start
- Sep 2025
- Primary completion
- Jan 2027
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of odronextamab in follicular lymphoma (FL). Primary endpoint: Complete Response Rate. Started Sep 2025; status: recruiting.
02
Drugs
odronextamab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT07128641.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07128641.